Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125578 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT02125578 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 69 participants.
The verdict
NCT02125578, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The primary objectives are to identify the highest safe and well-tolerated dose and frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV).
Interventions
- DRUG Placebo
- DRUG BIIB017 (PEGylated Interferon Beta-1a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02125578
The ClinicalTrials.gov registry entry for NCT02125578 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02125578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02125578 about?
NCT02125578 is a clinical study titled "A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers". The primary objectives are to identify the highest safe and well-tolerated dose and frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV).
What is the current status of trial NCT02125578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2008-03. Estimated completion is 2008-05.
What interventions are being tested in trial NCT02125578?
The interventions under investigation include: Placebo (DRUG), BIIB017 (PEGylated Interferon Beta-1a) (DRUG).
Who is sponsoring clinical trial NCT02125578?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.